Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

ACT Brief: The Evolving CRA Role, New Immunotherapy Standard in Gastric Cancer, and Priority Review for Higher-Dose Wegovy

3:00
 
Share
 

Manage episode 522185345 series 3665342
Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the FDA’s approval of Imfinzi plus FLOT as the first immunotherapy regimen for resectable gastric and GEJ cancers, and look at Novo Nordisk’s fast-tracked submission of its higher-dose Wegovy injectable under the Commissioner’s Priority Review Program.
  continue reading

106 episodes

Artwork
iconShare
 
Manage episode 522185345 series 3665342
Content provided by Audioboom and Applied Clinical Trials. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Audioboom and Applied Clinical Trials or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In today’s ACT Brief, we examine how the CRA role is transforming alongside modern clinical trial technology, review the FDA’s approval of Imfinzi plus FLOT as the first immunotherapy regimen for resectable gastric and GEJ cancers, and look at Novo Nordisk’s fast-tracked submission of its higher-dose Wegovy injectable under the Commissioner’s Priority Review Program.
  continue reading

106 episodes

كل الحلقات

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play